UBS Group
STOK icon

UBS Group’s Stoke Therapeutics STOK Stock Holding History

UBS Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-31,000
Closed -$1.2M – 9800
2021
Q1 		$1.2M Buy
31,000
+9,100
+42% +$518K ﹤0.01% 4074
2020
Q4 		$1.36M Buy
+21,900
New +$1M ﹤0.01% 3760

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's STOK Position: Q2 2026 in Review

UBS Group increased its Stoke Therapeutics (STOK) stake by 31% in Q2 2026, buying an estimated $1.57M and bringing the position to 207,112 shares worth $6.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3858.

UBS Group first reported a position in STOK in Q2 2019 and has held it in 25 quarters since. The position peaked at $7.19M in Q3 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • UBS Group held 207,112 shares of Stoke Therapeutics worth $6.78M as of Q2 2026.
  • UBS Group bought 48,808 Stoke Therapeutics shares in Q2 2026, an estimated $1.57M.
  • Stoke Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3858 holding.
  • UBS Group first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 25 quarters since.
  • UBS Group's Stoke Therapeutics position peaked at $7.19M in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.